𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Frequency and clinical significance of transition zone cancer in prostate cancer screening

✍ Scribed by Reissigl, Andreas; Pointner, Josef; Strasser, Hannes; Ennemoser, Othmar; Klocker, Helmut; Bartsch, Georg


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
626 KB
Volume
30
Category
Article
ISSN
0270-4137

No coin nor oath required. For personal study only.

✦ Synopsis


Approximately 20% of prostate cancers originate in the transition zone (TZ). Although transrectal ultrasound (TRUS) and systematic biopsies have improved peripheral zone (PZ) cancer diagnosis, additional biopsies directed into the TZ may further improve cancer detection.

To evaluate the frequency and clinical significance of TZ cancers, we added two TZ biopsies to the routinely performed sextant biopsies. Three hundred forty patients (aged 45-75) from our prostate-specific antigen (PSA) screening study (21,078 volunteers) with negative rectal examination findings underwent systematic and TZ biopsies with threedimensional ultrasound equipment. All patients had elevated PSA levels according to agespecific reference ranges. Ninety-eight of 340 men (28.5%) had biopsies positive for cancer. Of these 98 cancers, 28 (28%) originated in the TZ only and 5 (5%) were located in the TZ as well as the PZ. Eight men showed TZ abnormalities on ultrasound images, of whom four had biopsies positive for TZ cancer. The TZ cancers detected were pathologically significant in 96% (27 of 28). Seventy-one percent (20 of 28) of pathologically staged cancers were found to be organ confined and all combined TZ and PZ cancers were advanced tumors.

We conclude that TZ biopsies enhance the cancer detection rate in prostate cancer screening and should therefore be added to the routinely done sextant biopsies in men with PSA elevation and normal digital rectal examination findings.


πŸ“œ SIMILAR VOLUMES


Localized prostate cancer. Relationship
✍ Thomas A. Stamey; Fuad S. Freiha; John E. McNeal; Elise A. Redwine; Alice S. Whi πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 561 KB

Background. Using the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute and American total mortality rates, the authors calculated the probability at birth of having a diagnosis of prostate cancer within a man's life to be 8.8% and then subtracted the incidence of

Prostate-specific antigen in screening o
✍ Dr. T. Ming Chu πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 467 KB πŸ‘ 1 views

Prostate-specific antigen (PSA) is a wellcharacterized human prostate-specific glycoprotein. PSA has been shown to be the most effective immunohistologic marker for prostate cancer, as well as the most useful serologic test in staging and monitoring prostate cancer and in early detection of recurren

LRIG1 and the liar paradox in prostate c
✍ Marcus Thomasson; Baofeng Wang; Peter Hammarsten; Anna Dahlman; Jenny Liao Perss πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 487 KB πŸ‘ 1 views

## Abstract The course of prostate cancer varies greatly, and additional prognostic markers are needed. Leucine‐rich repeats and immunoglobulin‐like domains protein 1 (LRIG1) is an endogenous inhibitor of growth factor signaling and a proposed tumor suppressor. Publicly available gene expression da

Clinical and biological significance of
✍ Shailesh Singh; Rajesh Singh; Udai P. Singh; Shesh N. Rai; Kristian R. Novakovic πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 466 KB πŸ‘ 1 views

## Abstract Chemokines and chemokine receptors have been shown to be involved in metastatic process of prostate cancer (PCa). In this study, we show primary PCa tissues and cell lines (LNCaP and PC3) express CXCR5, a specific chemokine receptor for CXCL13. Expression of CXCR5 was significantly high